Saturday, 31 October 2026European Markets

MOLTEN VENTURES Stock 10.2% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with MOLTEN VENTURES (GRW.IR) rising 10.2% to €3.24 on Friday, after five sequential sessions in a row of losses. ISEQ All Share jumped 0.5% to €8,798.37, following the last session's downward trend on what was a somewhat bullish trend exchanging session today.

MOLTEN VENTURES's last close was €2.94, 42.35% under its 52-week high of €5.10.

About MOLTEN VENTURES

Molten Ventures Plc, formerly known as Draper Esprit plc, is a private equity and venture capital firm specializing in any stage in the lifecycle of a business from seed and series A stage, growth capital to pre-IPO investments, late stage, start-ups, cross-stage investments, buyouts, PIPES, and also makes direct and secondary investments in portfolio companies. It also seeks to buy entire funds from other tech investors. The firm primarily invests in companies from pre-revenue stage upwards. It primarily invests in technology oriented business. The firm typically invests in digital technology, consumer, commerce, enterprise and data, systems and semiconductors, financial technology, internet, mobile, media, telecom, consumer technology, enterprise technology, SaaS, fintech, deeptech, digital health & wellness and healthcare sectors, prop tech, software, hardware, medical technology, and life sciences sectors. It invests in companies based in Europe, United states, Austria, Belgium, Denmark, Germany, Finland, France, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, Ireland, and United Kingdom. The firm seeks to invest between $0.02 million and €10 million ($10.88 million) in rounds up to €1 million ($1.09 million) and €30 million ($32.63 million). It invests 30 percent of its corpus in very early stage companies with less than $5 million in revenues. The firm seeks to make minority and majority investments. Molten Ventures Plc was founded in 1984 and is based in London, United Kingdom with an additional offices in Dublin, Ireland.

Earnings Per Share

As for profitability, MOLTEN VENTURES has a trailing twelve months EPS of €-1.2.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -18.52%.

Moving Average

MOLTEN VENTURES's worth is way above its 50-day moving average of €2.73 and below its 200-day moving average of €3.39.

Volume

Today's last reported volume for MOLTEN VENTURES is 155 which is 53.46% above its average volume of 101.

Yearly Top and Bottom Value

MOLTEN VENTURES's stock is valued at €3.24 at 21:33 EST, way below its 52-week high of €5.10 and way higher than its 52-week low of €2.44.

More news about MOLTEN VENTURES (GRW.IR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com